IN2012DN01378A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01378A IN2012DN01378A IN1378DEN2012A IN2012DN01378A IN 2012DN01378 A IN2012DN01378 A IN 2012DN01378A IN 1378DEN2012 A IN1378DEN2012 A IN 1378DEN2012A IN 2012DN01378 A IN2012DN01378 A IN 2012DN01378A
- Authority
- IN
- India
- Prior art keywords
- piperazinedione
- apaf
- prophylaxis
- apoptosis
- pathological
- Prior art date
Links
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 abstract 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200901757 | 2009-07-30 | ||
| PCT/ES2010/000349 WO2011012746A2 (es) | 2009-07-30 | 2010-07-29 | Compuestos inhibidores de apaf-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01378A true IN2012DN01378A (https=) | 2015-06-05 |
Family
ID=43529761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1378DEN2012 IN2012DN01378A (https=) | 2009-07-30 | 2010-07-29 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9040701B2 (https=) |
| EP (1) | EP2460798B1 (https=) |
| JP (1) | JP5694320B2 (https=) |
| KR (1) | KR101786761B1 (https=) |
| CN (1) | CN102574818B (https=) |
| AU (1) | AU2010277505B2 (https=) |
| BR (1) | BR112012002134B8 (https=) |
| CA (1) | CA2769408C (https=) |
| EA (1) | EA021838B1 (https=) |
| ES (1) | ES2727711T3 (https=) |
| IN (1) | IN2012DN01378A (https=) |
| MX (1) | MX2012001339A (https=) |
| NZ (1) | NZ598125A (https=) |
| TR (1) | TR201907804T4 (https=) |
| WO (1) | WO2011012746A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006487B2 (en) | 2005-06-15 | 2015-04-14 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| EP2609135A4 (en) | 2010-08-26 | 2015-05-20 | Massachusetts Inst Technology | POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| KR102451116B1 (ko) | 2011-10-27 | 2022-10-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체 |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| ES2443538B1 (es) * | 2012-07-19 | 2014-11-26 | Consejo Superior De Investigaciones Cientificas (Csic) | Compuestos beta-lactámicos inhibidores de APAF1 |
| EP2882706A1 (en) | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
| KR20210122917A (ko) | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| PL3467108T3 (pl) | 2013-03-14 | 2024-09-30 | Translate Bio, Inc. | Sposoby oczyszczania informacyjnego rna |
| WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| MX2016005238A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Formulaciones de lipidos para la administracion de acido ribonucleico mensajero. |
| PT3134506T (pt) | 2014-04-25 | 2019-10-31 | Translate Bio Inc | Métodos de purificação de rna mensageiro |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| EP3160959B1 (en) | 2014-06-24 | 2023-08-30 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| ES2949540T3 (es) | 2015-06-19 | 2023-09-29 | Massachusetts Inst Technology | 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| AU2019256527B2 (en) | 2018-04-19 | 2025-01-23 | Spiral Therapeutics, Inc. | Inner ear drug delivery devices and methods of use |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| WO2020176419A1 (en) | 2019-02-25 | 2020-09-03 | Spiral Therapeutics, Inc. | Intratympanic injector devices and needles for delivery of drugs and methods of use |
| CN115515542B (zh) | 2020-01-24 | 2026-02-06 | 斯皮拉尔诊疗有限公司 | 用于耳科的装置、系统和方法 |
| EP4137131A1 (en) * | 2021-08-17 | 2023-02-22 | Centre National de la Recherche Scientifique (CNRS) | Novel serotonin analogues and their uses for treating iron-associated disorders |
| CN115124449B (zh) * | 2022-05-24 | 2024-02-02 | 上海英诺富成生物科技有限公司 | 一种吲哚化合物及制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560503A (en) * | 1968-09-18 | 1971-02-02 | Council Scient Ind Res | Di-lower alkyl-substituted octahydropyrazinopyrimidinones |
| GB1284582A (en) | 1969-11-10 | 1972-08-09 | Council Scient Ind Res | Substituted piperazinopyrimidinones |
| JPH04234375A (ja) | 1990-12-27 | 1992-08-24 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物及びその製造法 |
| HUT68769A (en) * | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
| JPH05117246A (ja) | 1991-10-23 | 1993-05-14 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法 |
| WO1996000391A1 (en) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Methods for the synthesis of diketopiperazines |
| DE60201415T2 (de) * | 2001-01-19 | 2006-02-09 | Pharmacopeia, Inc. | Bisarylderivate mit fsh rezeptor modulierender aktivität |
| NZ539735A (en) | 2002-10-02 | 2009-07-31 | Dmi Biosciences Inc | Diagnosis and monitoring of diseases using markers, such as diketopiperazines |
| US20070128687A1 (en) * | 2003-11-28 | 2007-06-07 | Hajime Ikeda | Process for producing dipeptides |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
| ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
-
2010
- 2010-07-29 BR BR112012002134A patent/BR112012002134B8/pt not_active IP Right Cessation
- 2010-07-29 EP EP10803937.1A patent/EP2460798B1/en active Active
- 2010-07-29 CN CN201080043254.1A patent/CN102574818B/zh not_active Expired - Fee Related
- 2010-07-29 IN IN1378DEN2012 patent/IN2012DN01378A/en unknown
- 2010-07-29 JP JP2012522195A patent/JP5694320B2/ja not_active Expired - Fee Related
- 2010-07-29 EA EA201270215A patent/EA021838B1/ru not_active IP Right Cessation
- 2010-07-29 NZ NZ598125A patent/NZ598125A/en not_active IP Right Cessation
- 2010-07-29 WO PCT/ES2010/000349 patent/WO2011012746A2/es not_active Ceased
- 2010-07-29 KR KR1020127005131A patent/KR101786761B1/ko not_active Expired - Fee Related
- 2010-07-29 MX MX2012001339A patent/MX2012001339A/es active IP Right Grant
- 2010-07-29 TR TR2019/07804T patent/TR201907804T4/tr unknown
- 2010-07-29 AU AU2010277505A patent/AU2010277505B2/en not_active Ceased
- 2010-07-29 CA CA2769408A patent/CA2769408C/en active Active
- 2010-07-29 ES ES10803937T patent/ES2727711T3/es active Active
- 2010-07-29 US US13/387,240 patent/US9040701B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TR201907804T4 (tr) | 2019-06-21 |
| KR20120052354A (ko) | 2012-05-23 |
| US20120122868A1 (en) | 2012-05-17 |
| BR112012002134A2 (pt) | 2016-05-31 |
| KR101786761B1 (ko) | 2017-10-18 |
| US9040701B2 (en) | 2015-05-26 |
| AU2010277505B2 (en) | 2016-01-14 |
| WO2011012746A3 (es) | 2011-07-14 |
| MX2012001339A (es) | 2012-03-07 |
| JP2013500314A (ja) | 2013-01-07 |
| JP5694320B2 (ja) | 2015-04-01 |
| EA021838B1 (ru) | 2015-09-30 |
| AU2010277505A1 (en) | 2012-03-08 |
| EA201270215A1 (ru) | 2012-11-30 |
| CN102574818B (zh) | 2015-02-25 |
| ES2727711T3 (es) | 2019-10-18 |
| WO2011012746A2 (es) | 2011-02-03 |
| BR112012002134B8 (pt) | 2021-05-25 |
| CA2769408A1 (en) | 2011-02-03 |
| NZ598125A (en) | 2014-05-30 |
| BR112012002134B1 (pt) | 2021-03-02 |
| EP2460798A4 (en) | 2013-02-27 |
| CN102574818A (zh) | 2012-07-11 |
| EP2460798A2 (en) | 2012-06-06 |
| CA2769408C (en) | 2017-09-05 |
| EP2460798B1 (en) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01378A (https=) | ||
| IN2012DN01233A (https=) | ||
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| MX2014012695A (es) | Derivados de isoindolona. | |
| MX2010006241A (es) | Derivados de aminotriazol como agonistas de alx. | |
| EA201300684A1 (ru) | Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1 | |
| UA105036C2 (uk) | Амінотетралінові похідні, фармацевтична композиція, яка їх містить, і їх застосування в терапії | |
| MX2011012122A (es) | Derivados de tiofeno. | |
| MX339759B (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| MX2009007104A (es) | Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina. | |
| PT2150530E (pt) | Derivados de sulfonamida substituídos | |
| MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
| GEAP201914546A (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| MX2010008021A (es) | Nuevos derivados de n-(2-amino-fenil)-amida. | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
| GEP20156346B (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| GEP201606514B (en) | Apoptosis inhibitors and usage thereof | |
| MX2009006913A (es) | Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico. | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| TN2012000242A1 (en) | Heterocyclic sulfonamide derivatives | |
| TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| MX2012006287A (es) | Activadores de azaindol glucocinasa. | |
| MX2010002680A (es) | Uso de derivados de purina para la manufactura de un medicamento. | |
| PT1975158E (pt) | Novos derivados de pirrole com actividade inibidora de histona desacetilase |